STAT News

NOVEMBER 4, 2022

His goal was to find a treatment for his brother’s form of Duchenne muscular dystrophy, which is caused by a mutation that impeded his ability to make a crucial muscle protein called dystrophin. Many scientists hope that the approach proves to be a safer alternative to gene editing therapies that make permanent changes to DNA itself.

Gene Editing 105

Gene Editing Gene Gene Therapy Scientist 105

XTalks

NOVEMBER 23, 2021

The expansion will include a new 30,000-square-foot building that will be able to produce 160 million doses of an mRNA vaccine per year, and up to 70 million prepared and packaged fill finish doses for commercial distribution annually. Additional production would be performed at other facilities for final packaging.

Manufacturing 98

Manufacturing Vaccination Vaccine Drugs 98

XTalks

FEBRUARY 11, 2021

The drugmaker is targeting various steps in the manufacturing process, beginning right at the DNA stage, which is required as the template from which the mRNA for the SARS-CoV-2 spike protein in the vaccine is made. This involves testing and quality assurance of the DNA to make sure its integrity meets the strict vaccine requirements.

Manufacturing 52

Manufacturing Vaccination Vaccine DNA 52

Pfizer

AUGUST 15, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide. 07.27.2022.

Drugs 99

Drugs Vaccine Vaccination In-Vitro 99

Pfizer

DECEMBER 13, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide.

Drugs 110

Drugs Licensing Licensing Production 110

The Pharma Data

OCTOBER 14, 2020

Assistant Professor of Medical Sciences at Columbia University Vagelos College of Physicians and Surgeons, is designed to generate DNA aptamer-based anti-idiotypes to selected monoclonal antibodies identified in Dr. Ilya Trakht’s study. The study led by Dr. Sergei Rudchenko, Ph.D., About TNX-1800.

Vaccination 40

Vaccination Vaccine Development Medicine 40

XTalks

AUGUST 2, 2023

2) Paxlovid (nirmatrelvir/ritonavir) Paxlovid is a dual-packaged oral medication for the treatment of COVID-19. Johnson & Johnson’s Top 5 Best-Selling Drugs of 2022: 1) Stelara (ustekinumab) Stelara is an immunosuppressant biologic therapy that blocks the IL-12 and IL-23 proteins that play a role in plaque psoriasis and Crohn’s disease.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

AUGUST 3, 2021

We are very pleased that our comprehensive nonclinical data package has addressed all issues identified related to DRG toxicity and the FDA has reached the decision that we may proceed with our OAV-101 IT clinical trial program and initiate the STEER trial,” said Shephard Mpofu, M.D., SVP, Chief Medical Officer, Novartis Gene Therapies.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Therapy Gene 52

Pfizer

JANUARY 27, 2023

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus.

Marketing 75

Marketing Production Drugs Licensing 75

The Pharma Data

SEPTEMBER 1, 2020

About antigen testing An antigen test detects proteins which are structural or functional components of a pathogen and are thus very specific to that pathogen. SARS-CoV-2 Rapid Antigen Test package insert [2] European Centre for Disease Prevention and Control. Results are ready in only 15 minutes. References [1] Roche Diagnostics Ltd.

In-Vitro 52

In-Vitro Antibody Medicine Clinical Trials 52

Pfizer

DECEMBER 20, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide.

Drugs 69

Drugs Licensing Licensing Containment 69

XTalks

FEBRUARY 11, 2021

For example, British scientist Rosalind Franklin gained recognition for her work after her death, which is not unheard of, but with it came the revelation that her work, which helped demonstrate the double helical structure of DNA, went largely uncredited by famed DNA duo James Watson and Francis Crick.

Genetics 119

Genetics DNA Genomics Genome 119

The Pharma Data

AUGUST 3, 2021

The company confirmed the tirzepatide SURPASS program has met global regulatory submission requirements for evaluating cardiovascular risk and its intention to submit the registration package to regulatory authorities by the end of 2021. The company announced the acquisition of Protomer Technologies Inc.,

Antibody 52

Antibody Sales Development Production 52

Pfizer

NOVEMBER 23, 2022

In preclinical studies, nirmatrelvir did not demonstrate evidence of mutagenic DNA interactions. Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. Microsomal triglyceride transfer protein inhibitor: lomitapide.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

XTalks

SEPTEMBER 14, 2020

The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The University of Oxford/AstraZeneca partnership, in turn, is testing a viral-vectored coronavirus vaccine that again expresses the spike protein of SARS-CoV-2 virus. And stimulus packages continue.

Vaccination 92

Vaccination Vaccine Antibody Life Science 92